Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
52.94 USD | -0.56% | -11.75% | +92.51% |
Jun. 03 | Merus Says Target Tumors in Lung Cancer Patients Decrease in Size After MCLA-129 Treatment | MT |
Jun. 03 | Truist Securities Raises Price Target on Merus to $88 From $69, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+92.51% | 3.53B | |
+15.55% | 118B | |
+12.66% | 106B | |
-2.53% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.92% | 15.56B | |
+6.19% | 13.63B | |
+28.83% | 12.27B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- Merus Pancreatic Cancer Treatment Gets FDA Breakthrough Therapy Designation; Shares Jump Premarket